Paul Raeburn/FairWarning On Oct. 26, 2005, Alfred Caronia, a sales consultant for a little-known pharmaceutical company based in California, met with a doctor to discuss promotion of one of the firm’s drugs. The drug, a depressant called Xyrem, had been approved by the U.S. Food and Drug Administration to treat only certain patients with the […]